Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 228 clinical trials
featured
Metastatic Castration Resistant Prostate Cancer

People with Prostate Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 0 views
  • 06 Aug, 2021
  • 1 location
featured
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies

  • 110 views
  • 08 Nov, 2020
  • 1 location
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).

  • 2 views
  • 30 Aug, 2021
  • 14 locations
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

prostate adenocarcinoma
androgen suppression
abiraterone
gonadotropin releasing hormone
serum testosterone
  • 200 views
  • 19 Aug, 2021
  • 198 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, …

prostate adenocarcinoma
prednisone
abiraterone
serum testosterone
solid tumour
  • 0 views
  • 22 Sep, 2021
  • 18 locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with

  • 2496 views
  • 24 Jul, 2021
  • 210 locations
Study to Evaluate the Safety Tolerability Pharmacokinetics and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide in Patients With Metastatic Castration Resistant Prostate Cancer

metastatic castration resistant prostate cancer. In this study, this investigational medication will be administered to patients for the first time. The primary objective of the study is to define the safety

  • 12 views
  • 22 Sep, 2021
  • 10 locations
A Study of ASP1948 Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent …

  • 134 views
  • 08 Sep, 2021
  • 69 locations
A Study of ASP1951 in Subjects With Advanced Solid Tumors

The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and …

  • 28 views
  • 12 Sep, 2021
  • 32 locations
Investigation of Radium-223 Dichloride (Xofigo) a Treatment That Gives Off Radiation That Helps Kill Cancer Cells Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of …

  • 0 views
  • 08 Sep, 2021
  • 146 locations